BMY

46.02

0.11% -0.05

Handel nachbörslich: 45.93 -0.09 -0.20%

Bristol Myers Squibb Co (BMY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BMY? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$46.07

Offen:

$46.2

24-Stunden-Volumen:

20.36M

Relative Volume:

1.41

Marktkapitalisierung:

$93.67B

Einnahmen:

$48.03B

Nettoeinkommen (Verlust:

$6.05B

KGV:

15.54

EPS:

2.9615

Netto-Cashflow:

$15.30B

1W Leistung:

+6.06%

1M Leistung:

+1.25%

6M Leistung:

-9.00%

1J Leistung:

-15.28%

1-Tages-Spanne:

$45.51

$46.66

1-Wochen-Bereich:

$42.52

$46.66

52-Wochen-Spanne:

$42.52

$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Firmenname

Bristol Myers Squibb Co

Sektor

Healthcare (1136)

Branche

Drug Manufacturers - General (19)

Telefon

(609) 252-4621

Adresse

ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY

Mitarbeiter

34,100

Twitter

@BMSNEWS

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

BMY's Discussions on Twitter

Vergleichen Sie BMY mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BMY Bristol Myers Squibb Co	46.02	93.79B	48.03B	6.05B	15.30B	2.9615
LLY Lilly Eli Co	896.53	772.28B	59.42B	18.41B	6.44B	20.22
JNJ Johnson Johnson	186.26	455.04B	92.15B	25.12B	20.46B	10.36
ABBV Abbvie Inc	211.96	385.18B	59.64B	2.37B	18.24B	1.331
NVS Novartis Ag Adr	123.86	237.53B	54.45B	14.42B	17.15B	7.333
MRK Merck Co Inc	82.49	214.76B	63.99B	19.05B	14.72B	7.5596

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-05	Herabstufung	Daiwa Securities	Outperform → Neutral
2025-04-22	Eingeleitet	Cantor Fitzgerald	Neutral
2025-04-22	Eingeleitet	Piper Sandler	Overweight
2024-12-16	Hochstufung	Jefferies	Hold → Buy
2024-12-10	Fortgesetzt	BofA Securities	Neutral
2024-11-15	Eingeleitet	Wolfe Research	Peer Perform
2024-11-13	Hochstufung	Daiwa Securities	Neutral → Outperform
2024-11-12	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-10-25	Herabstufung	Citigroup	Buy → Neutral
2024-10-17	Eingeleitet	Bernstein	Mkt Perform
2024-07-29	Herabstufung	Barclays	Overweight → Equal Weight
2024-03-11	Herabstufung	Societe Generale	Buy → Hold
2024-02-06	Herabstufung	Redburn Atlantic	Buy → Neutral
2024-01-03	Herabstufung	BofA Securities	Buy → Neutral
2023-11-15	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-11-02	Herabstufung	Daiwa Securities	Outperform → Neutral
2023-10-27	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2023-10-27	Hochstufung	HSBC Securities	Reduce → Hold
2023-10-27	Herabstufung	William Blair	Outperform → Mkt Perform
2023-10-20	Fortgesetzt	UBS	Neutral
2023-07-14	Eingeleitet	HSBC Securities	Reduce
2023-07-10	Eingeleitet	SVB Securities	Market Perform
2023-06-28	Eingeleitet	Daiwa Securities	Outperform
2023-03-06	Eingeleitet	Jefferies	Hold
2023-01-17	Eingeleitet	Cantor Fitzgerald	Overweight
2022-11-18	Eingeleitet	Credit Suisse	Neutral
2022-10-10	Herabstufung	Guggenheim	Buy → Neutral
2022-09-14	Herabstufung	Berenberg	Buy → Hold
2022-06-03	Herabstufung	Raymond James	Outperform → Mkt Perform
2022-04-06	Fortgesetzt	Morgan Stanley	Underweight
2021-12-17	Eingeleitet	Goldman	Buy
2021-12-09	Fortgesetzt	Wells Fargo	Equal Weight
2021-11-19	Eingeleitet	BMO Capital Markets	Outperform
2021-11-01	Herabstufung	Argus	Buy → Hold
2021-07-27	Fortgesetzt	Truist	Buy
2021-04-30	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-04-13	Hochstufung	Truist	Hold → Buy
2020-11-16	Hochstufung	Societe Generale	Hold → Buy
2020-11-10	Fortgesetzt	Bernstein	Mkt Perform
2020-11-06	Herabstufung	Gabelli & Co	Buy → Hold
2020-10-19	Hochstufung	Guggenheim	Neutral → Buy
2020-09-29	Eingeleitet	Berenberg	Buy
2020-07-28	Eingeleitet	Raymond James	Outperform
2020-04-02	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-03-23	Herabstufung	Societe Generale	Buy → Hold
2020-02-27	Eingeleitet	Barclays	Equal Weight
2020-01-06	Fortgesetzt	Citigroup	Buy
2019-12-13	Hochstufung	Argus	Hold → Buy
2019-11-22	Fortgesetzt	Morgan Stanley	Equal-Weight
2019-10-17	Fortgesetzt	BofA/Merrill	Buy
2019-08-14	Hochstufung	Atlantic Equities	Neutral → Overweight
2019-05-28	Eingeleitet	Goldman	Buy
2019-05-20	Herabstufung	Argus	Buy → Hold
2019-05-03	Hochstufung	Barclays	Equal Weight → Overweight
2019-05-03	Fortgesetzt	JP Morgan	Overweight
2019-01-15	Hochstufung	Societe Generale	Sell → Buy
2018-10-22	Herabstufung	Citigroup	Buy → Neutral

Alle ansehen

Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten

Nov 03, 2025

Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth - Seeking Alpha

Nov 03, 2025

BioNTech Boosts 2025 Outlook as Cancer Drug Alliance with Bristol Myers Squibb Takes Aim at Merck’s Keytruda - Tekedia

Nov 03, 2025

Pulmonary Fibrosis Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, A - Barchart.com

Nov 03, 2025

Balanced Outlook on Bristol-Myers Squibb: Strong Q3 Performance Amid ADEPT-2 Trial Concerns - TipRanks

Nov 03, 2025

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership - inkl

Nov 03, 2025

Bristol Myers Squibb to present Camzyos efficacy data at AHA scientific sessions - Investing.com

Nov 03, 2025

Bristol-Myers Squibb stock rises 7% after clean earnings beat By Investing.com - Investing.com Nigeria

Nov 03, 2025

United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceuticals, Astellas Pharma, Baxter, Pfizer, Dr. Reddy's LaboratoriesResearchAndMarkets.com - Business Wire

Nov 03, 2025

US Cancer Immunotherapy Forecast and Company Analysis Report 2025-2033 Featuring Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Pfizer, Novartis, Johnson & Johnson, Eli Lily Co, Seattle GeneticsResearchAndMarkets.com - FinancialContent

Nov 03, 2025

Bristol-Myers Squibb stock rises 7% after clean earnings beat - Investing.com

Nov 03, 2025

Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades' - Benzinga

Nov 03, 2025

Verity Asset Management Inc. Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat

Nov 03, 2025

Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025 - Business Wire

Nov 03, 2025

BioNTech raises 2025 revenue guidance after Bristol Myers deal By Investing.com - Investing.com Nigeria

Nov 03, 2025

Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes - The AI Journal

Nov 03, 2025

Nov 02, 2025

Published on: 2025-11-02 22:42:16 - newser.com

Nov 02, 2025

How Bristol Myers Squibb Company (BRM) stock moves in volatile trading sessionsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com

Nov 02, 2025

Syverson Strege & Co Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat

Nov 02, 2025

Assetmark Inc. Lowers Holdings in Bristol Myers Squibb Company $BMY - MarketBeat

Nov 02, 2025

What’s the recovery path for long term holders of Bristol Myers Squibb Company Equity RightTrade Signal Summary & Technical Pattern Alert System - newser.com

Nov 02, 2025

Bristol-Myers Squibb Company (NYSE:BMY) Q3 2025 Earnings Call Transcript - Insider Monkey

Nov 02, 2025

Nov 01, 2025

Can Bristol Myers Squibb Company stock hit record highs againExit Point & Entry Point Confirmation Signals - newser.com

Nov 01, 2025

Bristol Myers Squibb Co. Hits New 52-Week Low at $42.52 - Markets Mojo

Nov 01, 2025

Bristol Myers Squibb Company recovery potential after sell offWeekly Market Report & Risk Controlled Daily Trade Plans - newser.com

Nov 01, 2025

Is Bristol Myers Squibb Company Celegne Contingent stock a fit for income portfolios2025 Market Overview & Comprehensive Market Scan Insights - newser.com

Nov 01, 2025

Oct 31, 2025

Bristol-Myers Squibb Company (BMY.MX) stock price, news, quote and history - Yahoo! Finance UK

Oct 31, 2025

Bristol Myers Squibb (NYSE:BMY) Posts Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat

Oct 31, 2025

Bristol Myers Squibb Stock Hits Day High with 7.09% Surge - Markets Mojo

Oct 31, 2025

S&P 500 Falls 0.99% Amid 1,651 Advancing Stocks; Bristol Myers Soars 7.09% - Markets Mojo

Oct 31, 2025

Bristol-Myers Squibb Tops Forecasts But Leaves Questions Unanswered - Finimize

Oct 31, 2025

Germ Cell Tumors Market: Epidemiology, Therapies, Companies – DelveInsight | Featuring Takeda, Novartis, Bristol Myers Squibb, Merck & Co., Roche, and Bayer - Barchart.com

Oct 31, 2025

Retirement Systems of Alabama Has $60.37 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat

Oct 31, 2025

New launches focus of latest financial prints at BMS, Merck & Co. - FirstWord Pharma

Oct 31, 2025

Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data - Insider Monkey

Oct 31, 2025